Kang KH, Lebow ES, Niemierko A, et al. - The efficacy of proton therapy in the management of head and neck paragangliomas (HNPG) was determined. From 1997 to 2016, researchers included 37 patients and 40 tumors treated with proton therapy. The patients received proton therapy at a median of 50.4 Gy (range: 45-68). Having a genetic/family predisposition for HNPG was noted to be correlated with multifocal tumors and younger diagnosis age. Outcomes support the efficacy and safety of proton therapy in treating patients with HNPGs, with excellent tumor control, successful volumetric tumor reduction, and symptomatic improvement. The 5-year recurrence-free and overall survival rates were both 97%. Subjective hearing impairment (19%), middle ear inflammation (14%), and dry mouth (8%) were the grade 2 to grade 3 toxicities (54%) reported in this work.